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Essentials 
The number of manuscripts published on COVI-19 is overwhelming. 
Social media allows sharing of information rapidly. 
Twitter offers one of the best ways to remain up to date. 
The reach of Twitter is far greater than print information ever achieves.  
 
Abstract 
COVID-19 is the most serious pandemic of the internet era. The number of scientific 
manuscripts published on the subject daily has been overwhelming. The use of twitter 
enables interested health professionals and the public to stay informed. 
 
Background 
COVID-19, the infection caused by a new corona virus SARS-CoV-2, was first identified in the 
Wuhan province of China and declared a pandemic by the World Health Organisation 
(WHO) on the 12th March 2020 (1). It is thought that the virus originated from an animal 
species, most likely the bat, which is a reservoir for this type of virus (2). At the time of 
writing, over 7 million persons have been infected worldwide and over 400,000 have died. 
The infection leads to primarily respiratory symptoms and the elderly, men, those with 
comorbidities, the obese, immunosuppressed and persons from Black and other ethnic 
minorities are disproportionately affected with severe COVID-19 (1,3). In this commentary, I 
will discuss the value of twitter in keeping users up to date and helping them identify trends 
of relevance to haemostasis and thrombosis. 
 
Information overload and dissemination 
The COVID-19 pandemic has resulted in a tsunami of information in scientific journals as 
well as on social media. During any pandemic the thirst for information is almost as great as 
the search for treatments. During the 1918 Spanish flu pandemic, when the main way for 
disseminating information was through print media, newspapers released up to six editions 
daily. In 2020, constant delivery of information is made possible through the almost 
universal availability of the internet. The only thing that outstrips the exponential number of 
new SARS-CoV-2 infections, is the number of new pieces of information about the virus 
published daily online or in print. There are now many ways to communicate including 
television, radio, newspapers, journals and multiple social media platforms. 
One way to keep up with the massive amount of available information is through the use of 
twitter which has very wide, instantaneous reach. Twitter divides people with users 
swearing by it and non-users thinking it a waste of time. In my view, twitter is now one of 
the most important ways to share knowledge with other scientists and the public, both 
rapidly and simultaneously.  The number of manuscripts published on COVID-19 has been 
huge with more than 300 per day during May 2020 (Figure 1); it is impossible for a single 
individual to read them all. Twitter has been invaluable in helping to identify and share the 
most important ones.  
 
Twitter in science communication 
The reach of standard publications in science is relatively small, slow and not always in a 
format that would be understandable to most people. Twitter facilitates this by being 
widespread, quick and simple. Since the start of the pandemic almost 11 million tweets 
have been posted that included the hashtag #COVID19. An example of a tweet and its reach 
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is shown in figure 2. I started tweeting about COVID-19 to try and stay up to date in a very 
rapidly moving field and to share information I thought was important with a wider 
audience, both health professionals and the public. As it can be seen in table 1, each tweet 
is read by thousands of persons and the number of impressions per month are many times 
higher than scientific publications in journals can ever achieve. 
 
The role of pulmonary microthrombi in the underlying pathogenicity 
SARS-CoV-2 is an RNA virus that enters the cell through its receptor angiotensin-converting 
enzyme 2 (ACE-2) after which it is internalised. ACE-2 converts the vasoconstrictor 
angiotensin II (Ang II) to angiotensin 1-7, a vasodilator. Following infection, ACE-2 is 
downregulated and the resulting increase in Ang II contributes to endothelial damage. 
Endothelial damage is one of the critical elements in SARS-CoV-2 pathogenicity changing the 
microenvironment from thromboprotective to highly prothrombotic (4). The increasingly 
prothrombotic environment leads to pulmonary microthrombi in a process termed 
Pulmonary Intravascular Coagulation (PIC). PIC leads to impaired oxygen exchange and 
respiratory failure (5).  
 
D-Dimer, thrombotic risk and heparin use to prevent thrombosis 
The initial publications from China recognised coagulation activation as being very common 
in COVID-19 (6). The D-Dimer level on hospital admission correlated with disease severity 
and progressive elevation in the intensive care unit (ICU) patients correlated with death (7). 
The use of heparin prophylaxis, which was not initially routinely used in China, was 
associated with improved overall survival (7). What was at first not reported from China, 
was the very high prevalence of pulmonary emboli in patients in the ICU (Table 2). It is not 
clear if this was due to a reduced thrombotic risk in Chinese patients or the lack of 
systematic investigation of patients for thrombosis.  Subsequent reports from Europe have 
shown that the risk of venous thrombosis both in terms of pulmonary embolism and deep 
vein thrombosis is very high.  Given this high risk, it is imperative to offer all COVID-19 
patients admitted to hospital pharmacological thromboprophylaxis with LMWH, unless 
contraindicated. Many groups and societies have produced anticoagulation guidelines which 
are invariably based on clinical opinion rather than evidence of benefit. Among the non 
evidence-based guideline variations used are doubling the prophylactic LMWH dose, giving 
therapeutic anticoagulation on ICU admission and increasing anticoagulation based on a 
specific D-Dimer level. It can be difficult to radiologically image deteriorating ICU patients 
and often treatment dose LMWH is administered without objective evidence of a thrombus.  
The D-Dimer elevation reflects the thrombo-inflammatory process and has not been used 
previously as a test to alter the anticoagulation dose. If rapidly rising, the D-Dimer could be 
an indicator for the development of VTE and the need for imaging, but I do not believe it 
should form the basis for anticoagulation in isolation. 
 
The amplification of reach of standard publications by social media 
Social media can amplify the reach of published papers and one way to quantify this is 
through the use of the Altmetric Score of each paper. Altmetric Scores are a weighted count 
of online non-scholarly attention including mentions in mainstream news, public policy 
documents, Wikipedia, social networks and blogs (17). The Altmetric Score of original 
cardiovascular articles in the eight highest Web of Science Impact Factor journals have a 
median score of 10 (interquartile range 2-37) (17). 
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The Tang et al paper (6) mentioned above has been cited 215 times since its online release 
on 19 February 2020 and has an Altmetric Score of 594. It has had 633 tweets from 491 
users with an upper bound of 1,078,516 impressions. It is unlikely that a paper published in 
the Journal of Thrombosis and Haemostasis would have reached more than 1 million people 
without the use of social media. 
The second Tang et al paper (7) has been cited 151 times since its release on 27 March 2020 
and has an Altmetric Score of 1382. It has received 1788 tweets from 1509 users with an 
upper bound of impressions of 3,180, 846 which is even more impressive as it relates to 
treatment.  
 
 
The need for RCTs, even in a pandemic 
Faced with a disease that has an ICU mortality of 30-50%, a large number of off-label drugs 
have been used alone or in combination, based on theoretical or in vitro evidence of 
possible benefit. Randomised trials have been uncommon and these drugs have been used 
largely outside clinical studies. The result is that many patient populations worldwide have 
been repeatedly exposed to the same non-effective medications. Had a good quality 
randomised controlled study been done initially, thousands of patients worldwide might 
have been spared these ineffective treatments subsequently. However tempting it is to try 
something in a critical situation, all drugs have adverse effects and these can be 
detrimental. The call for RCTs in epidemics and pandemics is not new and most of the 
arguments we have seen with COVID-19, were also suggested during previous epidemics 
(18). 
 
The exit strategy 
This will have an impact on all of us and the lessons from the 1918 Spanish Flu pandemic, 
where early abandonment of isolation measures resulted in a larger second wave of 
infections that killed more people, must not be forgotten (19). Countries are dealing with 
the loosening of lockdowns differently, claiming to follow scientific advice, and often 
interpreting the evidence in different ways. These decisions cannot be separated from the 
economic ones and politicians take responsibility for making them. Implementation of 
testing, tracking and isolating contacts should be essential to limit infections. Many believe 
that the way out of the SARS-CoV-2 era will be through the use of a vaccine, even though 
there is no certainty that an effective one will be available. Twitter is the ideal platform for 
dissemination of information about rapid developments, which would be impossible to 
achieve at the same rate in the traditional scientific print journals. 
 
 
Long term complications 
One aspect of SARS-CoV-2 infection that has not made an impact in the print literature yet 
but which has gained traction on social media, is the long-term complications in patients 
with COVID-19 pneumonia, especially in those who have required ventilation. It is essential 
that these patients are followed up prospectively to identify problems related to pulmonary, 
vascular, psychological, cardiac and neurocognitive systems. Of major interest will be the 
frequency of long-term interstitial lung disease and pulmonary hypertension. It is assumed 
that COVID-19 related PE can be treated with 3 months anticoagulation as this is a transient 
risk factor, but this may not be the case, and the long-term thrombotic risk may be higher. 
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Conclusion 
COVID-19 is the most serious pandemic of the internet era. The number of scientific 
manuscripts published on the subject daily has been overwhelming. The use of twitter 
enables interested health professionals and the public to stay informed. Pulmonary micro 
and macrovascular thromboses are very frequent and contribute to the pathogenicity and 
mortality of the disorder. However tempting the desire to give highest doses of 
anticoagulation is, the real value of this therapy can only be determined through RCTs.   
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Figure 1: The number of publications listed on PubMed with the search term COVID-19. 
Over the same period almost 11 million tweets were posted using the same term.  
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Figure 2 Example of a tweet with the analysis provided by Twitter. Impressions is the total 
number the individual tweet has been seen by users. Engagements is the total number users 
interacted with a tweet such as by retweeting, replying, liking, opening a link etc. 
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Table 1 The number of tweets sent from @ProfMakris and the total number of impressions 
they achieved. 
 
 
 
Month in 2020 Number of tweets Total impressions Impressions per 
tweet 
February 128 463,000 3,617 
March 286 1,110,000 3,881 
April 358 1,590,000 4,441 
May 287 1,260,000 4,390 
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Table 2. Risk of thrombosis in hospitalised patients with COVID-19. Pharmacological prophylaxis was given in all studies except the one by Cui 
from China. 
 
 
Study Clinical 
diagnosis or 
screening  
Total patients 
n 
ICU patients 
n (%) 
Still 
in hospital 
n (%) 
PE 
n (%) 
DVT 
n (%) 
Total VTE 
n (%) 
Total 
arterial 
n (%) 
Cui (China) (8) Mixed 81 81 (100) 11 Not given 20 (24.7) 20 (24.7) Not given 
Ren (China) (9) Screening 48 48 (100) Not given Not given 41 (85.4) 
(*) 
41 (85.4) Not given 
Klok (Netherlands) 
(10) 
Clinical 184 184 (100) 65 (35.3) 65 (35.3) 3 (1.6) 68 (36.9) 3 (1.6) 
Middeldorp 
(Netherlands) (11) 
Mixed 198 75 (37.8) 16 (8.1) 13 (6.6) 25 (12.6) 39 (19.6) Not given 
Helms (France) (12) Clinical 150 150 (100) >101 (>67.3) 25 (16.7) 3 (2.0) 28 (18.6) 6 (4.0) 
Lodigiani (Italy) (13) Mixed 388 61 (15.7) Not given 10 (2.6) 6 (1.5) 16 (4.1) 13 (3.3) 
Thomas (UK) (14) Clinical 63 63 (100) >28 (>44.4) 5 (7.9) 1 (1.6) 6 (9.5) 2 (3.2) 
Longchamp 
(Switzerland) (15) 
Mixed 25 25 (100) 2 (8.0) 5 (20.0) 6 (24.0) 8 (32.0) Not given 
Demelo-Rodriguez 
(Spain) (16) 
Screening 156 0 (0) Not given 0 23 (14.7) 
(**) 
23 (14.7) Not given 
         
Total  1293 687  123 (9.5) 128 (9.9) 249 (19.2)  
 
(*) 5 of 48 (10.4%) were proximal DVT whilst 36 of 48 (75%) were isolated distal DVT detected by screening 
(**) 1 of 156 (0.6%) was proximal DVT whilst 22 or 156 (14.1%) were isolated distal DVT detected by screening 
